The Genomics Institute of the Novartis Research Foundation (GNF) serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization, the Novartis Institutes for BioMedical Research (NIBR). GNF’s nearly 600 scientists and engineers are committed to pushing the boundaries of science in pursuit of new medicines. Multi-disciplinary teams are focused on making advances in the areas of oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. GNF has world-class expertise in high-throughput drug screening, highly-parallel cell-based assays, and other advanced automation technologies, which enable its researchers to tackle the complexity of biological systems in seeking to address unmet medical need.